Inhibrx, Inc.

INBX

US45720L1070

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 12:28:47 27/06/2024 am IST			5-day change	1st Jan Change
14.67 ^USD	-2.78%		+3.57%	-61.34%

04/06	Inhibrx Biosciences Insider Bought Shares Worth $4,927,580, According to a Recent SEC Filing	MT
31/05	Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Biotechnology Select Industry Index	CI

Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P TMI Index

May 31, 2024

Latest news about Inhibrx, Inc.

Inhibrx Biosciences Insider Bought Shares Worth $4,927,580, According to a Recent SEC Filing	05/06	MT
Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Biotechnology Select Industry Index	31/05	CI
Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Global BMI Index	31/05	CI
Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P TMI Index	31/05	CI
Inhibrx, Inc. Announces Termination of Loan Agreement	31/05	CI
Inhibrx, Inc. Announces Management Changes	31/05	CI
Sanofi Closes Purchase of US Biotech Company Inhibrx	30/05	MT
Sanofi: acquisition of Inhibrx finalized	30/05	CF
Aventis Inc. completed the acquisition of Inhibrx, Inc. from a group of shareholders.	30/05	CI
Inhibrx, Inc. completed the Spin-Off of 92% stake in Inhibrx Biosciences, Inc..	29/05	CI
Inhibrx, Inc.(NasdaqGM:INBX) dropped from NASDAQ Biotechnology Index	29/05	CI
Inhibrx Shareholders Approve Sale of INBRX-101 Assets to Sanofi	25/05	MT
Inhibrx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Inhibrx Shares Fall After Q4 Net Loss Widens	28/02	MT
Earnings Flash (INBX) INHIBRX Reports Q4 Revenue $1.6M	28/02	MT
Inhibrx, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02	CI
Inhibrx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
Arecor Therapeutics hails Arestat as 2023 performance "strong"	01/02	AN
North American Morning Briefing : S&P 500 Futures Point to Fresh Record on Netflix Results	24/01	DJ
Health Care Flat After J&J Earnings -- Health Care Roundup	24/01	DJ
Arecor pleased as investee Inhibrx sells therapy to Sanofi	24/01	AN
Sector Update: Health Care Stocks Decline Late Afternoon	24/01	MT
Sector Update: Health Care	24/01	MT
Sanofi Agrees to Buy Inhibrx' Rare Disease Candidate For Up To $2.2 Billion	24/01	MT
CAC40: slight decline in the absence of catalysts	23/01	CF

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. The Companyâs clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that is designed with its proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist, being investigated as a single agent and in combination with Keytruda, a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to be an optimized agonist of this co-stimulatory receptor.

Sector

Biotechnology & Medical Research

Calendar

05/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
INHIBRX, INC.	-61.34%	1.79B
VERTEX PHARMACEUTICALS INCORPORATED	+16.56%	122B
REGENERON PHARMACEUTICALS, INC.	+21.60%	116B
ARGENX SE	+22.18%	27.03B
BIONTECH SE	-21.45%	20.36B
GENMAB A/S	-16.89%	16.43B
BEIGENE, LTD.	-18.17%	15.91B
WUXI APPTEC CO., LTD.	-44.74%	15.6B
SAREPTA THERAPEUTICS, INC.	+62.66%	14.94B
NEUROCRINE BIOSCIENCES, INC.	+3.42%	13.59B